FIORETTO, LUISA
 Distribuzione geografica
Continente #
EU - Europa 94
NA - Nord America 93
AS - Asia 49
SA - Sud America 3
Totale 239
Nazione #
US - Stati Uniti d'America 93
IE - Irlanda 27
PL - Polonia 26
HK - Hong Kong 25
IT - Italia 17
SE - Svezia 16
JO - Giordania 14
CN - Cina 5
RU - Federazione Russa 4
BR - Brasile 3
FI - Finlandia 2
IN - India 2
VN - Vietnam 2
CH - Svizzera 1
DE - Germania 1
SG - Singapore 1
Totale 239
Città #
Dublin 27
Warsaw 26
Hong Kong 22
Chandler 20
Florence 12
Ashburn 11
Seattle 7
Fairfield 5
West Jordan 5
Moscow 4
Hillsboro 3
São Paulo 3
Altamura 2
Ann Arbor 2
Cambridge 2
Dong Ket 2
Helsinki 2
Lawrence 2
New York 2
Pune 2
Redwood City 2
Washington 2
Beijing 1
Bern 1
Boston 1
Buffalo 1
Frankfurt am Main 1
Houston 1
Kent 1
Lucca 1
Princeton 1
Rome 1
Shanghai 1
Singapore 1
Totale 177
Nome #
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 92
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study 36
Phase I trial of a novel alkylating agent 29
Dose-finding study of gemcitabine and epirubicin in patients with advanced pancreatic cancer. 28
Pharmacokinetics and endocrine effects of leuprolide depot in advanced prostatic cancer: a dose-response analysis 25
Phase I clinical trial of a new alkylating agent, PTT-119 22
Preliminary results of a phase II multicenter study on the clinical efficacy and safety to the LH-RH analog leuprolide in the treatment of prostatic carcinoma 15
Totale 247
Categoria #
all - tutte 1.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.196


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 0 0 0 3 0
2020/202140 4 4 2 4 2 5 4 4 2 6 0 3
2021/20227 0 0 0 1 0 0 0 1 0 1 2 2
2022/2023121 1 8 1 17 13 28 18 5 22 0 3 5
2023/202473 2 5 8 0 6 10 0 29 1 7 5 0
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 247